- EF Hutton is assuming coverage of Sonnet BioTherapeutics Holdings Inc SONN with a Buy rating and a $6.70 price target.
- Sonnet has a protein engineering platform called FullyHuman Albumin Binding (FHAB), which utilizes a single-chain antibody fragment(scFv) to deliver one or two active drug compounds to maximize the benefits of cytokines against solid tumors.
- The analyst notes Sonnet’s lead clinical candidate, SON-1010, is designed to harness the potential ofIL-12, a regulator of T-cells and antibody-mediated immune responses.
- Clinical trials of recombinant human IL-12 were conducted as far back as the 1990s; however, despite intriguing signs of efficacy in solid tumors, single-agent therapy with the native molecule proved toxic.
- At the ACCR data presentation, Sonnet announced that the safety of SON-1010 dosing has been formally reviewed in both the current Phase 1 clinical trials, and the company is now enrolling the final dose cohort in the cancer trial.
- Of the 15 patients from the first five cohorts of SB101 evaluable for follow-up at this latest cutoff, 9 had stable disease at the first follow-up scan, 4 of which were already progressing at study entry.
- Price Action: SONN shares are up 35% at $0.39 on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in